Neuroscience Focus Areas:
Our other therapy areas

    • {%buzitemName%}
        {%buzbrandMenuItems%}
    • {%bitemName%} {%barrowSpan%}
        {%bsubBrandMenuItems%}
    • {%sbitemName%} {%sbarrowSpan%}
        {%sbproductMenuItems%}
    • {%pitemKeyName%} {%pitemBadges%} {%parrowSpan%}
      {%pselfProduct%}
    • {%mNavitemName%}
      • {%lScountries%}
    • {%allMenuItem%}
      • {%cSlanguages%}

      • This website is for UK Healthcare Professionals only

      This promotional material is intended for UK Healthcare Professionals only.
      BOTOX® (botulinum toxin type A) Prescribing Information and adverse event reporting information can be found below.

      NDO D 2
      NDO M 2

      UK-BUO-250027. DOP: May 2025.

      The Patient Experience: Neurogenic detrusor overactivity (NDO) can impact on patients' quality of life in many ways

      Definition of NDO: NDO is characterised by overactivity of the bladder due to a relevant neurological condition5,6

      Consequences of untreated NDO: impact on quality of life 7

      Adapted from Tubaro, 2004.7

      Adapted from Tubaro, 2004.7

      Consequences of untreated NDO7-9

      Adapted from Tubaro, 2004.7

      Adapted from Tubaro, 2004.7

      Spinal lesions caused by a trauma, such as spinal cord injury, or by a progressive neurological condition, such as multiple sclerosis can lead to NDO10,11

      Expanded Disability Status Scale12,13

      Adapted from Fowler et al, 200912

      Approximately 80% of patients with MS report some form of UI14
      Frequency, urgency and UI are all commonly reported

      62% of patients with MS have NDO without bladder outlet obstruction15

      Voiding LUTS are prevalent; in approximately 5–10% of patients, bladder symptoms are present at the onset of MS16

      BoNT/A: botulinum toxin type A; CIC: clean intermittent catheterisation; DDAVP: desmopressin; IDC: indwelling catheter; LUTS: lower urinary tract symptoms; MS: multiple sclerosis; NDO: neurogenic detrusor overactivity; QoL: quality of life; UI: urinary incontinence.

      LEARN ABOUT THE MANAGEMENT OF NDO

       

      References

      1. Allergan. Data on file. INT/0423/2016
      2. Aurora S K, Winner P et al. Onabotulinum toxin A for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program. Headache. 2011;51(9):1358-1373
      3. Blumenfeld A M, Stark R J et al. Long-term study of the efficacy and safety of Onabotulinum toxin A for the prevention of chronic migraine: COMPEL study. J Headache Pain. 2018;19(1):13
      4. AbbVie Data on file. Approval Dates for BOTOX® in UK. REF-112127.
      5. BOTOX® Summary of Product Characteristics. Available at: www.medicines.org.uk.
      6. Salvatore S et al. Pathophysiology of Urinary Incontinence, Faecal Incontinence and Pelvic Organ Prolapse. Abrams et al. Incontinence: 6th edition. 2017;50:1026 
      7. Tubaro A. Defining overactive bladder: epidemiology and burden of disease. Urology. 2004;64(suppl 6A);2–6
      8. de Seze M, Ruffion A et al. The neurogenic bladder in multiple sclerosis: review of the literature and proposal of management guidelines. Multiple Sclerosis. 2007;13:915–928
      9. Goldmark E, Niver B and Ginsberg D A. Neurogenic bladder: from diagnosis to management. Curr Urol Rep. 2014;15:448
      10. Cardozo L, et al. (Eds) Incontinence 7th Edition (2023). ICI-ICS. International Continence Society, Bristol UK, ISBN: 978-0-9569607-4-0
      11. Blok B, et al. EAU Guidelines on Neuro-Urology. 2025. Available at: https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Neuro-Urology-2025.pdf. Accessed June 2025.
      12. Fowler C J, Panicker JN et al. A UK consensus on the management of the bladder in multiple sclerosis. Postgrad Mrd J. 2009;85:552-559
      13. Multiple Sclerosis Trust. Expanded Disability Status Scale (EDSS). Available at: https://mstrust.org.uk/a-z/expanded-disability-status-scale-edss. Accessed June 2025.
      14. National MS Society. Bladder Dysfunction in Multiple Sclerosis. Available at: https://www.nationalmssociety.org/understanding-ms/what-is-ms/ms-symptoms/bladder-problems. Accessed June 2025.
      15. Kalsi V and Fowler C J. Therapy insight: bladder dysfunction associated with multiple sclerosis. Nature Clinical Practice Urology. 2005;2:492–501
      16. McCombe P A, Gordan T P and Jackson M W. Bladder dysfunction in multiple sclerosis. Expert Rev Neurotherap. 2009;9:331–340

       

      References

      1. Allergan. Data on file. INT/0423/2016
      2. Aurora S K, Winner P et al. Onabotulinum toxin A for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program. Headache. 2011;51(9):1358-1373
      3. Blumenfeld A M, Stark R J et al. Long-term study of the efficacy and safety of Onabotulinum toxin A for the prevention of chronic migraine: COMPEL study. J Headache Pain. 2018;19(1):13
      4. AbbVie Data on file. Approval Dates for BOTOX® in UK. REF-112127.
      5. BOTOX® Summary of Product Characteristics. Available at: www.medicines.org.uk.
      6. Salvatore S et al. Pathophysiology of Urinary Incontinence, Faecal Incontinence and Pelvic Organ Prolapse. Abrams et al. Incontinence: 6th edition. 2017;50:1026
      7. Tubaro A. Defining overactive bladder: epidemiology and burden of disease. Urology. 2004;64(suppl 6A);2–6
      8. de Seze M, Ruffion A et al. The neurogenic bladder in multiple sclerosis: review of the literature and proposal of management guidelines. Multiple Sclerosis. 2007;13:915–928
      9. Goldmark E, Niver B and Ginsberg D A. Neurogenic bladder: from diagnosis to management. Curr Urol Rep. 2014;15:448
      10. Cardozo L, et al. (Eds) Incontinence 7th Edition (2023). ICI-ICS. International Continence Society, Bristol UK, ISBN: 978-0-9569607-4-0
      11. Blok B, et al. EAU Guidelines on Neuro-Urology. 2025. Available at: https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Neuro-Urology-2025.pdf. Accessed June 2025.
      12. Fowler C J, Panicker JN et al. A UK consensus on the management of the bladder in multiple sclerosis. Postgrad Mrd J. 2009;85:552-559
      13. Multiple Sclerosis Trust. Expanded Disability Status Scale (EDSS). Available at: https://mstrust.org.uk/a-z/expanded-disability-status-scale-edss. Accessed June 2025.
      14. National MS Society. Bladder Dysfunction in Multiple Sclerosis. Available at: https://www.nationalmssociety.org/understanding-ms/what-is-ms/ms-symptoms/bladder-problems. Accessed June 2025.
      15. Kalsi V and Fowler C J. Therapy insight: bladder dysfunction associated with multiple sclerosis. Nature Clinical Practice Urology. 2005;2:492–501
      16. McCombe P A, Gordan T P and Jackson M W. Bladder dysfunction in multiple sclerosis. Expert Rev Neurotherap. 2009;9:331–340

      Please refer to the BOTOX® Summary of Product Characteristics for further information on adverse events, contraindications and special warnings and precautions for use. The BOTOX® Summary of Product Characteristics can be found here

      BOTOX® PRESCRIBING INFORMATION

      By clicking the link above you will leave the AbbVie Pro website and be taken to the eMC PI portal website.

      Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/

      Adverse events should also be reported to AbbVie on GBPV@abbvie.com 

       

      Date of preparation: June 2025. UK-BUO-250043.

       

       

      Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or via the MHRA Yellow Card app, available in the Google Play or Apple App Stores. Adverse events should also be reported to AbbVie on GBPV@abbvie.com

       

      This website is for UK Healthcare Professionals only

      UK-ABBV-250217. Date of preparation June 2025. This website has been developed and funded by AbbVie Ltd.

      © 2023 AbbVie Ltd. All rights reserved. Registered Number: 08004972 England.